APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Generic Drugs

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

Selected research

Market Outlook & Growth Opportunities

Global Generic Drugs Market Outlook and Growth Opportunities 2026

Report ID 17399476041 January 2026217 pages

Choose your research edition.

Industry ResearchGeneric Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Generic Drugs Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Generic Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Generic Drugs Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Generic Drugs Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

Market competition is not intense. Teva, Novartis – Sandoz, Mylan, Sun Pharmaceutical and Aspen are the leaders of the industry, with about 19% market shares.

North America is the largest consumption place, with a consumption market share nearly 44%. Following North America, Europe is the second largest consumption place with the consumption market share of 18%.

Read the full market overview

This report provides an overview of the global Generic Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Generic Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Generic Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Generic Drugs market.

Generic Drugs Segment by Company

Teva

Novartis - Sandoz

Mylan

Sun Pharmaceutical

Aspen

Fresenius Kabi

Pfizer (Hospira)

Sanofi

Aurobindo

Lupin

Dr. Reddy's

Apotex

Cipla

ENDO (Par Pharmaceutical)

Stada Arzneimittel

Krka Group

Nichi-Iko Pharmaceutical

Valeant

Zydus Cadila

Hikma

Pharmaniaga Berhad

Hovid Berhad

Duopharma Biotech

Kotra Pharma

HOE Pharmaceutical

Y.S.P. Industries

Generic Drugs Segment by Type

Prescription

Non-Prescription Drugs

Generic Drugs Segment by Application

Hospital

Clinic

Others

Generic Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Generic Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Generic Drugs key companies, revenue, market share, and recent developments.

3. To split the Generic Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Generic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Generic Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Generic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Generic Drugs industry.

Chapter 3: Detailed analysis of Generic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Generic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Generic Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Generic Drugs Industry Trends Table 2. Generic Drugs Industry Drivers Table 3. Generic Drugs Industry Opportunities and Challenges Table 4. Generic Drugs Industry Restraints Table 5. Global Generic Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Generic Drugs Revenue Share by Company (2021-2026) Table 7. Global Generic Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Generic Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Generic Drugs Company, Product Type & Application Table 10. Global Generic Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Generic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Prescription Table 15. Significant Companies of Non-Prescription Drugs Table 16. Global Generic Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Generic Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Generic Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Generic Drugs Sales Value Share by Type (2021-2026) Table 20. Global Generic Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Others Table 24. Global Generic Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Generic Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Generic Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Generic Drugs Sales Value Share by Application (2021-2026) Table 28. Global Generic Drugs Sales Value Share by Application (2027-2032) Table 29. Global Generic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Generic Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Generic Drugs Sales Value Share by Region (2021-2026) Table 32. Global Generic Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Generic Drugs Sales Value Share by Region (2027-2032) Table 34. Global Generic Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Generic Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Generic Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global Generic Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Generic Drugs Sales Value Market Share by Country (2027-2032) Table 39. Teva Company Information Table 40. Teva Business Overview Table 41. Teva Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Teva Generic Drugs Product Portfolio Table 43. Teva Recent Development Table 44. Novartis - Sandoz Company Information Table 45. Novartis - Sandoz Business Overview Table 46. Novartis - Sandoz Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Novartis - Sandoz Generic Drugs Product Portfolio Table 48. Novartis - Sandoz Recent Development Table 49. Mylan Company Information Table 50. Mylan Business Overview Table 51. Mylan Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Mylan Generic Drugs Product Portfolio Table 53. Mylan Recent Development Table 54. Sun Pharmaceutical Company Information Table 55. Sun Pharmaceutical Business Overview Table 56. Sun Pharmaceutical Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Sun Pharmaceutical Generic Drugs Product Portfolio Table 58. Sun Pharmaceutical Recent Development Table 59. Aspen Company Information Table 60. Aspen Business Overview Table 61. Aspen Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Aspen Generic Drugs Product Portfolio Table 63. Aspen Recent Development Table 64. Fresenius Kabi Company Information Table 65. Fresenius Kabi Business Overview Table 66. Fresenius Kabi Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Fresenius Kabi Generic Drugs Product Portfolio Table 68. Fresenius Kabi Recent Development Table 69. Pfizer (Hospira) Company Information Table 70. Pfizer (Hospira) Business Overview Table 71. Pfizer (Hospira) Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Pfizer (Hospira) Generic Drugs Product Portfolio Table 73. Pfizer (Hospira) Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sanofi Generic Drugs Product Portfolio Table 78. Sanofi Recent Development Table 79. Aurobindo Company Information Table 80. Aurobindo Business Overview Table 81. Aurobindo Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Aurobindo Generic Drugs Product Portfolio Table 83. Aurobindo Recent Development Table 84. Lupin Company Information Table 85. Lupin Business Overview Table 86. Lupin Generic Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Lupin Generic Drugs Product Portfolio Table 88. Lupin Recent Development Table 89. Dr. Reddy's Company Information Table 90. Dr. Reddy's Business Overview Table 91. Dr. Reddy's Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 92. Dr. Reddy's Generic Drugs Product Portfolio Table 93. Dr. Reddy's Recent Development Table 94. Apotex Company Information Table 95. Apotex Business Overview Table 96. Apotex Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 97. Apotex Generic Drugs Product Portfolio Table 98. Apotex Recent Development Table 99. Cipla Company Information Table 100. Cipla Business Overview Table 101. Cipla Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 102. Cipla Generic Drugs Product Portfolio Table 103. Cipla Recent Development Table 104. ENDO (Par Pharmaceutical) Company Information Table 105. ENDO (Par Pharmaceutical) Business Overview Table 106. ENDO (Par Pharmaceutical) Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 107. ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio Table 108. ENDO (Par Pharmaceutical) Recent Development Table 109. Stada Arzneimittel Company Information Table 110. Stada Arzneimittel Business Overview Table 111. Stada Arzneimittel Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 112. Stada Arzneimittel Generic Drugs Product Portfolio Table 113. Stada Arzneimittel Recent Development Table 114. Krka Group Company Information Table 115. Krka Group Business Overview Table 116. Krka Group Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 117. Krka Group Generic Drugs Product Portfolio Table 118. Krka Group Recent Development Table 119. Nichi-Iko Pharmaceutical Company Information Table 120. Nichi-Iko Pharmaceutical Business Overview Table 121. Nichi-Iko Pharmaceutical Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 122. Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio Table 123. Nichi-Iko Pharmaceutical Recent Development Table 124. Valeant Company Information Table 125. Valeant Business Overview Table 126. Valeant Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 127. Valeant Generic Drugs Product Portfolio Table 128. Valeant Recent Development Table 129. Zydus Cadila Company Information Table 130. Zydus Cadila Business Overview Table 131. Zydus Cadila Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 132. Zydus Cadila Generic Drugs Product Portfolio Table 133. Zydus Cadila Recent Development Table 134. Hikma Company Information Table 135. Hikma Business Overview Table 136. Hikma Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 137. Hikma Generic Drugs Product Portfolio Table 138. Hikma Recent Development Table 139. Pharmaniaga Berhad Company Information Table 140. Pharmaniaga Berhad Business Overview Table 141. Pharmaniaga Berhad Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 142. Pharmaniaga Berhad Generic Drugs Product Portfolio Table 143. Pharmaniaga Berhad Recent Development Table 144. Hovid Berhad Company Information Table 145. Hovid Berhad Business Overview Table 146. Hovid Berhad Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 147. Hovid Berhad Generic Drugs Product Portfolio Table 148. Hovid Berhad Recent Development Table 149. Duopharma Biotech Company Information Table 150. Duopharma Biotech Business Overview Table 151. Duopharma Biotech Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 152. Duopharma Biotech Generic Drugs Product Portfolio Table 153. Duopharma Biotech Recent Development Table 154. Kotra Pharma Company Information Table 155. Kotra Pharma Business Overview Table 156. Kotra Pharma Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 157. Kotra Pharma Generic Drugs Product Portfolio Table 158. Kotra Pharma Recent Development Table 159. HOE Pharmaceutical Company Information Table 160. HOE Pharmaceutical Business Overview Table 161. HOE Pharmaceutical Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 162. HOE Pharmaceutical Generic Drugs Product Portfolio Table 163. HOE Pharmaceutical Recent Development Table 164. Y.S.P. Industries Company Information Table 165. Y.S.P. Industries Business Overview Table 166. Y.S.P. Industries Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2021-2026) Table 167. Y.S.P. Industries Generic Drugs Product Portfolio Table 168. Y.S.P. Industries Recent Development Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Generic Drugs Product Image Figure 2. Global Generic Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Generic Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Generic Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Prescription Image Figure 8. Non-Prescription Drugs Image Figure 9. Global Generic Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Generic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Generic Drugs Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Generic Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Generic Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Generic Drugs Sales Value Share by Application (2021-2032) Figure 18. Global Generic Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Generic Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Generic Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America Generic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Generic Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Generic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Generic Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Generic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Generic Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America Generic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Generic Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Generic Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Generic Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Generic Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Generic Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription
  • Non-Prescription Drugs
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Teva
  • Novartis - Sandoz
  • Mylan
  • Sun Pharmaceutical
  • Aspen
  • Fresenius Kabi
  • Pfizer (Hospira)
  • Sanofi
  • Aurobindo
  • Lupin
  • Dr. Reddy's
  • Apotex
  • Cipla
  • ENDO (Par Pharmaceutical)
  • Stada Arzneimittel
  • Krka Group
  • Nichi-Iko Pharmaceutical
  • Valeant
  • Zydus Cadila
  • Hikma
  • Pharmaniaga Berhad
  • Hovid Berhad
  • Duopharma Biotech
  • Kotra Pharma
  • HOE Pharmaceutical
  • Y.S.P. Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Generic Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Generic Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Generic Drugs Market Dynamics
  1. 2.1 Generic Drugs Industry Trends
  2. 2.2 Generic Drugs Industry Drivers
  3. 2.3 Generic Drugs Industry Opportunities and Challenges
  4. 2.4 Generic Drugs Industry Restraints
3 Generic Drugs Market by Company
  1. 3.1 Global Generic Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Generic Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Generic Drugs Company Ranking (2024-2026)
  4. 3.4 Global Generic Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Generic Drugs Company Product Type and Application
  6. 3.6 Global Generic Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Generic Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Generic Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Generic Drugs Market by Type
  1. 4.1 Generic Drugs Type Introduction
  2. 4.1.1 Prescription
  3. 4.1.2 Non-Prescription Drugs
  4. 4.2 Global Generic Drugs Sales Value by Type
  5. 4.2.1 Global Generic Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Generic Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Generic Drugs Sales Value Share by Type (2021-2032)
5 Generic Drugs Market by Application
  1. 5.1 Generic Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Generic Drugs Sales Value by Application
  6. 5.2.1 Global Generic Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Generic Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Generic Drugs Sales Value Share by Application (2021-2032)
6 Generic Drugs Regional Value Analysis
  1. 6.1 Global Generic Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Generic Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Generic Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Generic Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Generic Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Generic Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Generic Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Generic Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Generic Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Generic Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Generic Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Generic Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Generic Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Generic Drugs Sales Value Share by Country, 2025 VS 2032
7 Generic Drugs Country-level Value Analysis
  1. 7.1 Global Generic Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Generic Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Generic Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Generic Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Generic Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Generic Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Generic Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Generic Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Generic Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Generic Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Generic Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Generic Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Generic Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Generic Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Generic Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Generic Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Generic Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Generic Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Generic Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Generic Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Generic Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Generic Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Generic Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Generic Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Generic Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Generic Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Generic Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Generic Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Generic Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Generic Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Generic Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Generic Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Generic Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Generic Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Generic Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Generic Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Generic Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Generic Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Generic Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Generic Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Generic Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Generic Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Generic Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Generic Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Generic Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Generic Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Generic Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Generic Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Generic Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Generic Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Generic Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Generic Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Generic Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Generic Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Generic Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Generic Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Generic Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Generic Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Generic Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Generic Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Generic Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Generic Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Generic Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Generic Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Generic Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Generic Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Generic Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Generic Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Generic Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Generic Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Generic Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Generic Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Generic Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Generic Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Generic Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Generic Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Generic Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Generic Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Generic Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Generic Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Generic Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Generic Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Generic Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Generic Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Generic Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Generic Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Generic Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Generic Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Generic Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Generic Drugs Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Novartis - Sandoz
  8. 8.2.1 Novartis - Sandoz Company Information
  9. 8.2.2 Novartis - Sandoz Business Overview
  10. 8.2.3 Novartis - Sandoz Generic Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
  12. 8.2.5 Novartis - Sandoz Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Generic Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Generic Drugs Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 Sun Pharmaceutical
  20. 8.4.1 Sun Pharmaceutical Company Information
  21. 8.4.2 Sun Pharmaceutical Business Overview
  22. 8.4.3 Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
  24. 8.4.5 Sun Pharmaceutical Recent Developments
  25. 8.5 Aspen
  26. 8.5.1 Aspen Company Information
  27. 8.5.2 Aspen Business Overview
  28. 8.5.3 Aspen Generic Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Aspen Generic Drugs Product Portfolio
  30. 8.5.5 Aspen Recent Developments
  31. 8.6 Fresenius Kabi
  32. 8.6.1 Fresenius Kabi Company Information
  33. 8.6.2 Fresenius Kabi Business Overview
  34. 8.6.3 Fresenius Kabi Generic Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Fresenius Kabi Generic Drugs Product Portfolio
  36. 8.6.5 Fresenius Kabi Recent Developments
  37. 8.7 Pfizer (Hospira)
  38. 8.7.1 Pfizer (Hospira) Company Information
  39. 8.7.2 Pfizer (Hospira) Business Overview
  40. 8.7.3 Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
  42. 8.7.5 Pfizer (Hospira) Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Generic Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Generic Drugs Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Aurobindo
  50. 8.9.1 Aurobindo Company Information
  51. 8.9.2 Aurobindo Business Overview
  52. 8.9.3 Aurobindo Generic Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Aurobindo Generic Drugs Product Portfolio
  54. 8.9.5 Aurobindo Recent Developments
  55. 8.10 Lupin
  56. 8.10.1 Lupin Company Information
  57. 8.10.2 Lupin Business Overview
  58. 8.10.3 Lupin Generic Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lupin Generic Drugs Product Portfolio
  60. 8.10.5 Lupin Recent Developments
  61. 8.11 Dr. Reddy's
  62. 8.11.1 Dr. Reddy's Company Information
  63. 8.11.2 Dr. Reddy's Business Overview
  64. 8.11.3 Dr. Reddy's Generic Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Dr. Reddy's Generic Drugs Product Portfolio
  66. 8.11.5 Dr. Reddy's Recent Developments
  67. 8.12 Apotex
  68. 8.12.1 Apotex Company Information
  69. 8.12.2 Apotex Business Overview
  70. 8.12.3 Apotex Generic Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Apotex Generic Drugs Product Portfolio
  72. 8.12.5 Apotex Recent Developments
  73. 8.13 Cipla
  74. 8.13.1 Cipla Company Information
  75. 8.13.2 Cipla Business Overview
  76. 8.13.3 Cipla Generic Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Cipla Generic Drugs Product Portfolio
  78. 8.13.5 Cipla Recent Developments
  79. 8.14 ENDO (Par Pharmaceutical)
  80. 8.14.1 ENDO (Par Pharmaceutical) Company Information
  81. 8.14.2 ENDO (Par Pharmaceutical) Business Overview
  82. 8.14.3 ENDO (Par Pharmaceutical) Generic Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
  84. 8.14.5 ENDO (Par Pharmaceutical) Recent Developments
  85. 8.15 Stada Arzneimittel
  86. 8.15.1 Stada Arzneimittel Company Information
  87. 8.15.2 Stada Arzneimittel Business Overview
  88. 8.15.3 Stada Arzneimittel Generic Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
  90. 8.15.5 Stada Arzneimittel Recent Developments
  91. 8.16 Krka Group
  92. 8.16.1 Krka Group Company Information
  93. 8.16.2 Krka Group Business Overview
  94. 8.16.3 Krka Group Generic Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Krka Group Generic Drugs Product Portfolio
  96. 8.16.5 Krka Group Recent Developments
  97. 8.17 Nichi-Iko Pharmaceutical
  98. 8.17.1 Nichi-Iko Pharmaceutical Company Information
  99. 8.17.2 Nichi-Iko Pharmaceutical Business Overview
  100. 8.17.3 Nichi-Iko Pharmaceutical Generic Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
  102. 8.17.5 Nichi-Iko Pharmaceutical Recent Developments
  103. 8.18 Valeant
  104. 8.18.1 Valeant Company Information
  105. 8.18.2 Valeant Business Overview
  106. 8.18.3 Valeant Generic Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Valeant Generic Drugs Product Portfolio
  108. 8.18.5 Valeant Recent Developments
  109. 8.19 Zydus Cadila
  110. 8.19.1 Zydus Cadila Company Information
  111. 8.19.2 Zydus Cadila Business Overview
  112. 8.19.3 Zydus Cadila Generic Drugs Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Zydus Cadila Generic Drugs Product Portfolio
  114. 8.19.5 Zydus Cadila Recent Developments
  115. 8.20 Hikma
  116. 8.20.1 Hikma Company Information
  117. 8.20.2 Hikma Business Overview
  118. 8.20.3 Hikma Generic Drugs Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Hikma Generic Drugs Product Portfolio
  120. 8.20.5 Hikma Recent Developments
  121. 8.21 Pharmaniaga Berhad
  122. 8.21.1 Pharmaniaga Berhad Company Information
  123. 8.21.2 Pharmaniaga Berhad Business Overview
  124. 8.21.3 Pharmaniaga Berhad Generic Drugs Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
  126. 8.21.5 Pharmaniaga Berhad Recent Developments
  127. 8.22 Hovid Berhad
  128. 8.22.1 Hovid Berhad Company Information
  129. 8.22.2 Hovid Berhad Business Overview
  130. 8.22.3 Hovid Berhad Generic Drugs Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Hovid Berhad Generic Drugs Product Portfolio
  132. 8.22.5 Hovid Berhad Recent Developments
  133. 8.23 Duopharma Biotech
  134. 8.23.1 Duopharma Biotech Company Information
  135. 8.23.2 Duopharma Biotech Business Overview
  136. 8.23.3 Duopharma Biotech Generic Drugs Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Duopharma Biotech Generic Drugs Product Portfolio
  138. 8.23.5 Duopharma Biotech Recent Developments
  139. 8.24 Kotra Pharma
  140. 8.24.1 Kotra Pharma Company Information
  141. 8.24.2 Kotra Pharma Business Overview
  142. 8.24.3 Kotra Pharma Generic Drugs Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Kotra Pharma Generic Drugs Product Portfolio
  144. 8.24.5 Kotra Pharma Recent Developments
  145. 8.25 HOE Pharmaceutical
  146. 8.25.1 HOE Pharmaceutical Company Information
  147. 8.25.2 HOE Pharmaceutical Business Overview
  148. 8.25.3 HOE Pharmaceutical Generic Drugs Revenue and Gross Margin (2021-2026)
  149. 8.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
  150. 8.25.5 HOE Pharmaceutical Recent Developments
  151. 8.26 Y.S.P. Industries
  152. 8.26.1 Y.S.P. Industries Company Information
  153. 8.26.2 Y.S.P. Industries Business Overview
  154. 8.26.3 Y.S.P. Industries Generic Drugs Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
  156. 8.26.5 Y.S.P. Industries Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst